OMass Therapeutics: The company raised $100 million of Series B venture funding in a deal led by GV, Sanofi Ventures, and Northpond Ventures on April 28, 2022. Oxford Spin-out Equity Management, Syncona, and Oxford Science Enterprises also participated in the round. The company is a developer of a structural mass spectrometry technology platform designed to discover novel medicines.
Ashvattha Therapeutics: The company raised $69 million of Series B venture funding from Huadong Medicine Company, Natural Capital Management, and Tribe Capital on April 27, 2022. Plum Alley Investments and other undisclosed investors also participated in the round. The company is a developer of a novel therapeutics platform designed to treat unmet medical needs in oncology, ophthalmology, and inflammatory diseases.
Apertura Gene Therapy: The company raised $67 million of Series A venture funding from Deerfield Management on April 26, 2022. The company is an operator of a biotechnology company intended to develop genetic medicines for treating currently intractable diseases.
Kelonia Therapeutics: The company raised $50 million of Series A venture funding from Alta Partners, Horizons Ventures, and Venrock on April 28, 2022. The company is pioneering a new wave of genetic medicines intended to provide a next-generation gene delivery platform.
Concert Health: The company raised $42 million of Series B venture funding in a deal led by Healthy Ventures, Vertical Venture Partners, and Define Ventures on April 26, 2022, putting the company’s pre-money valuation at $170 million. The company is a provider of behavioral health services designed to assist in screening, therapy, and psychiatric consultations.
Adona Medical: The company raised $37.5 million of Series B venture funding in a deal led by The Capital Partnership and Cormorant Asset Management on April 29, 2022. Picard Angst MedTech, Excelestar Ventures, AMED Ventures, and Shifamed angel investors also participated in the round. The company is a developer of innovative interventional approaches designed for curing heart failure.
Genome Insight: The company raised $23 million of Series B venture funding in a deal led by Dunamu & Partners on April 28, 2022. Signite Partners and six other investors also participated in the round. The company is a developer of a genome-based big data platform designed to pave the way for a new era of personalized precision medicine.
Theator: The company raised $22.7 million of Series A-2 venture funding from undisclosed investors on April 26, 2022, putting the company’s pre-money valuation at $110 million. The company is an operator of a surgical intelligence platform intended to provide surgeons with artificial intelligence-powered decision support tools.
Implicity: The company raised EUR 20.6 million of Series A venture funding in a deal led by Crédit Mutuel Innovation and Bpifrance on April 27, 2022, putting the company’s pre-money valuation at EUR 32.8 million. BNP Paribas Développement, Karista (France), Serena Capital, Siparex XAnge Venture, and other undisclosed investors also participated in the round. The company is a developer of a remote monitoring platform designed to provide smart monitoring of connected cardiac prostheses.
i-Lumen Scientific: The company raised $18 million of venture funding from Bios Partners and other undisclosed investors on April 26, 2022. The company is a developer of a retinal technology company designed to improve eyesight in patients whose vision has been impaired by dry age-related macular degeneration.
EnsoData: The company raised $10 million of venture funding from Inspire Medical Systems on April 27, 2022. The company is a developer of a clinical workflow software designed to analyze sleep data.
Signal 1: The company raised $10 million of venture funding in a deal led by TD Bank Group, Layer6, and Inovia Capital on April 25, 2022. Radical Ventures, Unity Health Services, Geoffrey Hinton, Nadir Mohamed, Chen Fong, Chris Albinson, and Joe Canavan also participated in the round. The company is a provider of hospital services intended to transform patient care through responsibly-deployed artificial intelligence.
NETRI: The company raised EUR 8 million of Series A venture funding from Neovacs, Polygone International, and Altana Investissements on April 26, 2022. Netangels, Banque Publique d’Investissement, Bpifrance, and other undisclosed investors also participated in the round. The company is a developer of versatile technologies designed to accelerate medical and pharmaceutical research.
Hemotune: The company raised CHF 7.3 million through a combination of debt and Series B1 venture funding in a deal led by Occident Group on April 26, 2022, putting the company’s pre-money valuation at CHF 10.8 million. The company is an operator of a medical device company intended to restore immune balance in septic shock and improve patient outcomes.
Forcefield Therapeutics: The company raised GBP 5.5 million of venture funding from Syncona on April 25, 2022. The company is a producer of medication drugs intended to treat heart disease.
Ictero Medical: The company raised $7.2 million of Series A venture funding in a deal led by MedTex Ventures on April 28, 2022, putting the company’s pre-money valuation at $9 million. S3 Ventures and other undisclosed investors also participated in the round. The company is a developer of a minimally invasive treatment designed to treat gallstone disease.
EarLens: The company raised $6 million of venture funding in the form of convertible debt from undisclosed investors on April 25, 2022. The company is a developer of a contact hearing technology device designed to change the current standard of care for sound performance.
Rhino Health: The company raised $5.7 million of venture funding from undisclosed investors on April 27, 2022. The company is a developer of healthcare software intended to empower healthcare artificial intelligence development and clinical translation.
DuraStat: The company raised $5 million of Series B venture funding from undisclosed investors on April 29, 2022. The company is a developer of medical devices designed for dural repairs.
TearClear: The company raised $5 million of venture funding in the form of convertible debt from undisclosed investors on April 26, 2022. The company is a producer of eye drugs developed with the goal of disrupting the way current topical medications are delivered to the ocular surface.
Cureatr: The company raised $3.3 million of venture funding in the form of convertible debt from undisclosed investors on April 26, 2022. The company is a developer of a cloud-based medication management software designed to optimize patient care.
Novel Microdevices: The company raised $3.1 million of Series A venture funding in the form of convertible debt from TEDCO and other undisclosed investors on April 28, 2022. The company is a developer of a handheld point-of-care medical device designed to facilitate molecular diagnostics.
Aloe Care Health: The company received an undisclosed amount of development capital from Hepco Capital Management on April 26, 2022. The company is a provider of an eldercare monitoring device intended for professional caregivers and families caring for loved ones.
SciTech Development: The company is in the process of raising venture funding in the form of convertible debt from undisclosed investors on April 26, 2022. The company is a developer of oncology and cancer drugs designed for diseases with limited therapeutic options.
